MacroGenics Management

Management criteria checks 3/4

MacroGenics' CEO is Scott Koenig, appointed in Sep 2001, has a tenure of 22.67 years. total yearly compensation is $3.71M, comprised of 19% salary and 81% bonuses, including company stock and options. directly owns 2.07% of the company’s shares, worth €5.45M. The average tenure of the management team and the board of directors is 7.3 years and 6.9 years respectively.

Key information

Scott Koenig

Chief executive officer

US$3.7m

Total compensation

CEO salary percentage	19.0%
CEO tenure	22.7yrs
CEO ownership	2.1%
Management average tenure	7.3yrs
Board average tenure	6.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Scott Koenig's remuneration changed compared to MacroGenics's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$23m
Dec 31 2023	US$4m	US$705k	-US$9m
Sep 30 2023	n/a	n/a	US$50m
Jun 30 2023	n/a	n/a	US$7m
Mar 31 2023	n/a	n/a	-US$91m
Dec 31 2022	US$5m	US$673k	-US$120m
Sep 30 2022	n/a	n/a	-US$191m
Jun 30 2022	n/a	n/a	-US$219m
Mar 31 2022	n/a	n/a	-US$217m
Dec 31 2021	US$5m	US$651k	-US$202m
Sep 30 2021	n/a	n/a	-US$146m
Jun 30 2021	n/a	n/a	-US$129m
Mar 31 2021	n/a	n/a	-US$136m
Dec 31 2020	US$3m	US$656k	-US$130m
Sep 30 2020	n/a	n/a	-US$158m
Jun 30 2020	n/a	n/a	-US$167m
Mar 31 2020	n/a	n/a	-US$152m
Dec 31 2019	US$5m	US$590k	-US$152m
Sep 30 2019	n/a	n/a	-US$166m
Jun 30 2019	n/a	n/a	-US$155m
Mar 31 2019	n/a	n/a	-US$167m
Dec 31 2018	US$5m	US$599k	-US$171m
Sep 30 2018	n/a	n/a	-US$21m
Jun 30 2018	n/a	n/a	-US$34m
Mar 31 2018	n/a	n/a	-US$32m
Dec 31 2017	US$3m	US$554k	-US$20m

Compensation vs Market: Scott's total compensation ($USD3.71M) is above average for companies of similar size in the German market ($USD717.70K).

Compensation vs Earnings: Scott's compensation has been consistent with company performance over the past year.

CEO

Scott Koenig (71 yo)

22.7yrs

Tenure

US$3,705,825

Compensation

Dr. Scott Koenig, M.D., Ph D., has been the President and Chief Executive Officer of Macrogenics, Inc. since September 2001. Dr. Koenig is Co-Founder of Macrogenics.He served as Senior Vice President of R...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Scott Koenig	President	22.7yrs	US$3.71m	2.07% $ 5.4m
James Karrels	Senior VP	16yrs	US$1.58m	0.27% $ 719.0k
Stephen Eck	Senior VP of Clinical Development & Chief Medical Officer	3.8yrs	US$1.75m	0.016% $ 41.1k
Eric Risser	Chief Operating Officer	2.3yrs	US$1.92m	0.062% $ 163.1k
Thomas Spitznagel	Senior Vice President of Technical Operations	1.5yrs	US$1.88m	0.013% $ 34.9k
Ezio Bonvini	Senior VP of Research & Chief Scientific Officer	7.7yrs	US$2.29m	0.16% $ 423.1k
Jeffrey Peters	Senior VP	6.9yrs	no data	0% $ 0
Lynn Cilinski	VP, Controller & Treasurer	20.6yrs	no data	0.0099% $ 26.1k

7.3yrs

Average Tenure

60.5yo

Average Age

Experienced Management: M55's management team is seasoned and experienced (7.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Scott Koenig	President	22.7yrs	US$3.71m	2.07% $ 5.4m
David Stump	Independent Director	10.7yrs	US$160.75k	0.0072% $ 18.9k
Federica O'Brien	Independent Director	3.3yrs	US$152.00k	0.0072% $ 18.9k
Edward Hurwitz	Independent Director	19.6yrs	US$147.63k	0.060% $ 157.6k
Margaret Liu	Independent Director	1.3yrs	US$318.32k	0.0072% $ 18.9k
William Heiden	Independent Chairman of the Board	2yrs	US$180.13k	0.0072% $ 18.9k
Meenu Chhabra Karson	Independent Director	1.3yrs	US$335.41k	0.0072% $ 18.9k
Scott Jackson	Independent Director	7.3yrs	US$167.63k	0.0072% $ 18.9k
Jay Siegel	Independent Director	6.5yrs	US$167.21k	0.0072% $ 18.9k
Karen Jean Ferrante	Independent Director	7.3yrs	US$135.75k	0.0072% $ 18.9k

6.9yrs

Average Tenure

65yo

Average Age

Experienced Board: M55's board of directors are considered experienced (6.9 years average tenure).

MacroGenics Management

Management criteria checks 3/4

Key information

Recent management updates

Insider recently bought €67k worth of stock

MacroGenics, Inc. Appoints Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors

Macrogenics, Inc. Approves the Appointment of Margaret Liu, M.D. to Serve as Director

Senior VP recently bought €95k worth of stock

MacroGenics, Inc. Announces Management Changes

Insufficient new directors

Recent updates

First quarter 2024 earnings released: US$0.84 loss per share (vs US$0.61 loss in 1Q 2023)

MacroGenics, Inc. Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures

Full year 2023 earnings released: US$0.15 loss per share (vs US$1.95 loss in FY 2022)

Investor sentiment improves as stock rises 15%

MacroGenics, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Investor sentiment improves as stock rises 20%

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 21%

Third quarter 2023 earnings released: EPS: US$0.28 (vs US$0.40 loss in 3Q 2022)

MacroGenics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Insider recently bought €67k worth of stock

Investor sentiment deteriorates as stock falls 16%

New major risk - Share price stability

Second quarter 2023 earnings released: EPS: US$0.93 (vs US$0.67 loss in 2Q 2022)

MacroGenics, Inc. to Report Q2, 2023 Results on Aug 09, 2023

First quarter 2023 earnings released: US$0.61 loss per share (vs US$1.08 loss in 1Q 2022)

MacroGenics, Inc. to Report Q1, 2023 Results on May 09, 2023

Full year 2022 earnings released: US$1.95 loss per share (vs US$3.37 loss in FY 2021)

Macrogenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients

MacroGenics, Inc. Appoints Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors

Macrogenics, Inc. Approves the Appointment of Margaret Liu, M.D. to Serve as Director

MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab

Third quarter 2022 earnings released: US$0.40 loss per share (vs US$0.86 loss in 3Q 2021)

MacroGenics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Second quarter 2022 earnings released: US$0.67 loss per share (vs US$0.67 loss in 2Q 2021)

MacroGenics, Inc. to Report Q2, 2022 Results on Aug 08, 2022

MacroGenics, Inc. Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer

Senior VP recently bought €95k worth of stock

MacroGenics, Inc. Announces Management Changes

First quarter 2022 earnings released: US$1.08 loss per share (vs US$0.90 loss in 1Q 2021)

Insufficient new directors

MacroGenics, Inc. to Report Q1, 2022 Results on May 03, 2022

MacroGenics, Inc., Annual General Meeting, May 19, 2022

MacroGenics, Inc. Announces Promotion of Eric Risser to Chief Operating Officer

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

MacroGenics, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Third quarter 2021 earnings released: US$0.86 loss per share (vs US$0.66 loss in 3Q 2020)

MacroGenics Announces Final Overall Survival Results from SOPHIA Study of MARGENZA in Patients with HER2-Positive Metastatic Breast Cancer

Second quarter 2021 earnings released: US$0.67 loss per share (vs US$0.94 loss in 2Q 2020)

Insufficient new directors

MacroGenics Announces Preliminary Clinical Results from Phase 1 Study of MGC018 to be Presented at ASCO Annual Meeting

First quarter 2021 earnings released: US$0.90 loss per share (vs US$0.91 loss in 1Q 2020)

Full year 2020 earnings released: US$2.47 loss per share (vs US$3.16 loss in FY 2019)

Revenue beats expectations

MacroGenics, Inc. Provides Update Proprietary Programs

New 90-day low: €16.00

MacroGenics, Inc. to Report Q4, 2020 Results on Feb 25, 2021

MacroGenics, Inc. Names Federica O’Brien to its Board of Directors

New 90-day low: €16.30

Macrogenics, Inc. Announces the Publication of Results from the Sophia Trial of Margenza

Macrogenics, Inc. Announces Research Collaboration and Global License Agreement to Develop Preclinical Bispecific Molecule with Janssen Biotech, Inc

MacroGenics, Inc. Announces FDA Approval of MARGENZA for Patients with Pretreated Metastatic HER2-Positive Breast Cancer

MacroGenics Presents Flotetuzumab Data in Patients with Refractory Acute Myeloid Leukemia At the 2020 ASH Annual Meeting

MacroGenics, Inc. and EVERSANA Announces Agreement to Support the Potential Launch and Commercialization of Margetuximab

Revenue beats expectations

Third quarter 2020 earnings released: US$0.66 loss per share

MacroGenics Announces Flotetuzumab and Tebotelimab Presentations at the ASH Annual Meeting 2020

MacroGenics, Inc. to Report Q3, 2020 Results on Nov 04, 2020

MacroGenics, Inc. Enters into A Commercial Supply Agreement with Incyte Corporation

MacroGenics Announces Flotetuzumab Publication in Blood Advances

New 90-day low: €20.80

New 90-day low: €21.00

MacroGenics Announces Publication of Flotetuzumab Interim Phase 1/2 Clinical Trial Results in Blood

MacroGenics Announces Development Milestone Achieved in Retifanlimab (MGA012) Collaboration with Incyte

MacroGenics, Inc. Announces Presentation of MGD019 Phase 1 Data at the ESMO Virtual Congress 2020

MacroGenics, Inc. announced that it has received funding from Havencrest Capital Management, LLC

MacroGenics, Inc. to Report Q2, 2020 Results on Jul 30, 2020

MacroGenics, Inc.(NasdaqGS:MGNX) dropped from Russell Microcap Index

MacroGenics, Inc.(NasdaqGS:MGNX) dropped from Russell Microcap Value Index